



Société Anonyme à Conseil d'Administration
au capital de 21 610 998,20 euros
Siège social: 49 boulevard du Général Martial Valin, 75015 Paris
RCS 410 910 095 Paris

Press Release

Temporary transfer of Valerio Therapeutics shares to the Penalty Bench from 16 May 2025

Paris (France), [22 May 2025] - Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO) informs its shareholders that due to the delay in the publication of its 2024 annual financial report and in accordance with article 7.3.1 of the Euronext Growth Rules, Euronext has taken the decision to transfer the shares of Valerio Therapeutics to the Penalty Bench compartment with effect from 16 May 2025.

The Company was informed of this decision by letter dated 14 May 2025. Removal from the Penalty Bench will be automatic once Valerio Therapeutics will have published its annual financial report for the year ended 31 December 2024.

As a reminder, Valerio Therapeutics announced in a press release on 5 May 2025 that it was postponing the publication of its annual financial report due to accounting difficulties regarding its US subsidiary.

Valerio Therapeutics will inform its shareholders as soon as possible of the new date of publication of the 2024 annual financial report and the definitive date of the General Meeting called to approve the accounts for the 2024 financial year.

For more information, visit www.valeriotx.com.

CONTACTS

Valerio Therapeutics

Investor Relations:

ir@valeriotx.com | +33 (0) 1 70 38 33 99
